Developer docs
API playgroundTry for free, no card

Search company profiles

Exela Pharma Sciences

Full company profile

uuid0008gee

Namestring
Exela Pharma Sciences
Legal namestring
Exela Pharma Sciences, LLC
Websiteurl
exelapharma.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Exela Pharma Sciences, founded in 2005 and headquartered in Lenoir, North Carolina, is a US-based specialty pharmaceutical company that develops, manufactures, and markets proprietary and generic sterile injectable products and provides integrated contract development and manufacturing (CDMO) services to pharmaceutical innovators. The company operates two business units from a single 400,000+ square foot cGMP campus: a Finished Drug Products portfolio of more than 20 sterile injectables across ANDA, 505(b)(2) NDA, NDA, and 503B pathways (key brands include AKOVAZ, ELCYS, GLYRX-PF, NIPRIDE RTU, Bloxiverz, and Sodium Bicarbonate Injection) and a CDMO services division covering R&D, quality and regulatory, aseptic fill-finish (vials, IV bags, pre-filled syringes, lyophilization), and warehouse and logistics.

The technology base centers on cGMP sterile injectable manufacturing with isolator-based aseptic processing, high-speed automated vial and pre-filled syringe filling, DEA Schedule II-V controlled substance handling, terminal sterilization via high-capacity autoclaves, ultra-low-temperature biorepository storage, and integrated quality systems (LIMS, Empower chromatography, electronic quality system, ERP). The company has passed more than 15 FDA inspections since 2010 and is also approved by HealthCanada and the Australian TGA. Manufacturing capacity exceeds 100 million sterilized units per year, with disclosed excess capacity available for CDMO opportunities.

Exela generates revenue through two streams: sale of its own branded and generic injectable products to hospitals and health systems, and contract development and manufacturing services sold directly to pharmaceutical and biotech innovators. Products are distributed through Premier's group purchasing organization, Civica Rx (1,000+ hospital members), direct sales to health systems (including 11 health systems that are also minority investors in the parent holding company), and the company's own Exela Direct Store e-commerce platform. Pricing is negotiated through GPO contracts and direct quotes on multi-year terms; no public price list exists. The company has been subject to several voluntary recalls between 2022 and 2025 (particulate matter, vial breakage, and a Class I defective crimp recall), which represent an ongoing quality-execution consideration.

Short descriptiontext

Exela Pharma Sciences is a US-based specialty pharmaceutical company founded in 2005 that develops and manufactures proprietary and generic sterile injectable products and provides integrated CDMO services from over 400,000 square feet of cGMP capacity in Lenoir, North Carolina, serving hospitals, health systems, and pharmaceutical innovators via Premier, Civica Rx, and direct channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersLenoir, United States
HQ citystring
Lenoir
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable manufacturing, pharmaceutical contract manufacturing, generic injectable products, aseptic fill-finish services, cGMP pharmaceutical production
Industry3 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Sterile Injectable Pharmaceuticals Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Proprietary and Generic Sterile Injectable Products
TypeOne Time License
Description

Exela manufactures and markets its own branded sterile injectable pharmaceutical products (ANDA, 505(b)(2) NDA, NDA, 503B) including sodium bicarbonate, caffeine citrate, ephedrine sulfate, glycopyrrolate, neostigmine, cysteine, and other injectables sold to healthcare providers and health systems.

exelapharma.com
2CDMO Contract Development and Manufacturing Services
TypeProfessional Services
Description

Exela provides contract development and manufacturing services to pharmaceutical companies, offering integrated drug formulation, analytical, aseptic fill-finish, lyophilization, and regulatory services from early-phase through commercialization.

exelapharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Exela-branded pharmaceutical products sold via GPO and direct accounts
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing negotiated through group purchasing organizations (Premier, HealthTrust, Vizient, etc.) and direct customer accounts. No public price list available.

exelapharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Exela Pharma Sciences develops, manufactures, and markets proprietary and generic sterile injectable pharmaceutical products in liquid vials, IV bags, lyophilized vials, and pre-filled syringes. The company also operates a CDMO business providing contract development, cGMP aseptic manufacturing, quality/regulatory, and warehouse/logistics services to pharmaceutical innovators from its Lenoir, North Carolina facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 100 million sterilized units per year manufacturing capacity with significant excess capacity for CDMO
+3 more records
Product overview1 text field

Exela Pharma Sciences operates two distinct business units: Finished Drug Products (proprietary and generic sterile injectables) and Contract Development and Manufacturing Organization (CDMO). The Finished Drug Products portfolio includes 20+ sterile injectable products marketed via ANDA, 505(b)(2) NDA, and 503b pathways. Key branded products include AKOVAZ (ephedrine sulfate), ELCYS (cysteine hydrochloride - only FDA approved cysteine injection), GLYRX-PF (glycopyrrolate), and NIPRIDE RTU (sodium nitroprusside). The CDMO services division provides end-to-end contract services including R&D (analytical, microbiology, formulation), cGMP manufacturing (vials, IV bags, prefilled syringes, lyophilization), quality/regulatory support, and warehouse/logistics from their Lenoir, NC facilities. The company manufactures liquid vials, lyophilized vials, IV bags, and pre-filled syringes.

Product and service16 records
1ELCYS (cysteine hydrochloride) Injection, USP
CategoryFinished Drug Product (NDA)
Description

500 mg/10mL (50 mg/mL) single-dose vial of cysteine hydrochloride injection used as an additive to amino acid solutions for TPN; the only FDA-approved cysteine hydrochloride injection in the US market with aluminum content of no more than 120 parts per billion, addressing aluminum toxicity risk in parenteral nutrition patients.

2AKOVAZ (ephedrine sulfate) Injection
CategoryFinished Drug Product (NDA)
Description

Ephedrine sulfate injection available in 25 mg/5mL pre-filled syringe and 50 mg/mL single-dose vial presentations; a clear, colorless, sterile solution used for pressor support during anesthesia.

3Bloxiverz (Neostigmine Methylsulfate) Prefilled Syringe
CategoryFinished Drug Product (ANDA)
Description

Pre-filled syringe of neostigmine methylsulfate injection USP for reversal of neuromuscular blockade following surgical procedures.

4GLYRX-PF (glycopyrrolate injection)
CategoryFinished Drug Product (NDA)
Description

Glycopyrrolate injection available in 1 mg/5mL pre-filled syringe, 0.2 mg/mL single-dose vial, and 0.4 mg/2mL single-dose vial presentations; used for anticholinergic indications including reduction of airway and gastric secretions during anesthesia.

5NIPRIDE RTU (sodium nitroprusside) Injection
CategoryFinished Drug Product (NDA)
Description

Ready-to-use sodium nitroprusside injection in 50 mg/100mL (0.5 mg/mL) and 20 mg/100mL (0.2 mg/mL) amber single-dose vials; sterile, unpreserved, colorless to red-brown solution for immediate blood pressure control.

6Sodium Bicarbonate Injection, USP
CategoryFinished Drug Product (ANDA)
Description

Sodium bicarbonate injection in 4.2% (5 mEq/10mL) and 8.4% (50 mEq/50mL and 10 mEq/10mL) single-dose vial presentations; clear, sterile, nonpyrogenic, hypertonic solution for treatment of metabolic acidosis.

7Caffeine Citrate Injection and Oral Solution, USP
CategoryFinished Drug Product (ANDA)
Description

Caffeine citrate 60 mg/3mL (20 mg/mL) injection vial and oral solution for treatment of neonatal apnea in premature infants.

8Tranexamic Acid Injection, IV Bag
CategoryFinished Drug Product (ANDA)
Description

Tranexamic acid 1000 mg/100mL (10 mg/mL) single-dose polymeric IV bag for antifibrinolytic therapy to reduce or prevent hemorrhage.

9Potassium Acetate Injection, USP
CategoryFinished Drug Product (ANDA)
Description

Potassium acetate injection USP in 40 mEq/20mL (2 mEq/mL) single-dose vials and 200 mEq/100mL (2 mEq/mL) pharmacy bulk vials for electrolyte replacement in IV admixtures.

10Verapamil Hydrochloride Injection, USP
CategoryFinished Drug Product (ANDA)
Description

Verapamil hydrochloride injection USP 5 mg/2mL (2.5 mg/mL) single-dose vial for antiarrhythmic and cardiovascular use.

11Cupric Chloride Injection, USP
CategoryFinished Drug Product (ANDA)
Description

Cupric chloride injection USP 4mg/10mL (0.4 mg/mL) single-dose plastic vial of sterile, nonpyrogenic solution for trace element supplementation in parenteral nutrition.

12Zinc Chloride Injection, USP
CategoryFinished Drug Product (ANDA)
Description

Zinc chloride injection USP 10 mg/10mL (1 mg/mL) single-dose vial for trace element supplementation in parenteral nutrition.

13CDMO Research and Development Services
CategoryCDMO Service
Description

Full-service R&D offering including small and large molecule capabilities, analytical services, microbiology labs, drug formulation development, and pre-formulation studies for parenteral, liquid, and lyophilized formulations; serves pharmaceutical and biotech innovators.

14CDMO cGMP Manufacturing Services
CategoryCDMO Service
Description

cGMP parenteral drug product contract manufacturing including medium- and high-speed vial filling, IV bag filling, pre-filled syringe filling, lyophilization, aseptic and terminal sterilization, Schedule II-IV DEA controlled substance handling, stability programs, and automated inspection/labeling/packaging.

15CDMO Quality and Regulatory Services
CategoryCDMO Service
Description

Quality and regulatory support with 15+ FDA inspections since 2010, experience with 505(b)(2) NDAs and ANDAs, regulatory filings for sterile injections, electronic quality systems, and pharmacovigilance for life science innovators.

16CDMO Warehouse and Logistics Services
CategoryCDMO Service
Description

Warehousing, biorepository storage at ultra-low temperatures (-80°C to -70°C) and 2-8°C, temperature-controlled storage, global distribution, and cold chain capabilities for pharmaceutical and biotech customers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-09-11
Description

Civica Rx, a non-profit organization formed in 2018 with mission to solve chronic drug shortages, signed a long-term agreement with Exela for distribution of Sodium Bicarbonate Injection to Civica's 1,000+ hospital members under the Civica label. Distribution began Q4 2019.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Amphastar is a US-based specialty pharmaceutical company focused on injectable, inhalation, and intranasal products, including generic sterile injectables sold to hospitals. It directly overlaps with Exela's proprietary/generic sterile injectable portfolio and its hospital-channel GTM motion.

TypeDirect peer
Description

Fresenius Kabi is a global leader in sterile injectable generics, IV solutions, and parenteral nutrition, selling to hospitals and health systems worldwide. It competes head-to-head with Exela in generic sterile injectables (e.g., sodium bicarbonate) and large-volume parenterals sold through GPOs.

TypeDirect peer
Description

Hikma is a multinational generic pharmaceutical manufacturer with a large US injectable portfolio sold to hospitals. It directly competes with Exela's branded and generic sterile injectable products through similar GPO and hospital channels.

TypeDirect peer
Description

B. Braun is a major manufacturer of sterile injectables, IV solutions, and parenteral nutrition products with significant US manufacturing capacity. It competes directly with Exela in the hospital sterile injectable space and also operates its own CDMO capabilities.

TypeBroad incumbent
Description

Pfizer's Injectables portfolio, inherited from Hospira, is the largest US hospital injectable franchise, offering a broad sterile injectable portfolio plus global CDMO services. It overlaps with Exela's portfolio and CDMO business as a much larger incumbent player.

TypeDirect peer
Description

Catalent is a major global CDMO offering sterile fill-finish, prefilled syringe, and lyophilization services to pharma and biotech innovators. It competes with Exela's CDMO services for sterile injectable development and manufacturing contracts.

TypeDirect peer
Description

Patheon, now part of Thermo Fisher's pharma services segment, is a leading global CDMO offering sterile injectable development, aseptic fill-finish, and commercial manufacturing. It directly competes with Exela's CDMO services for biotech and pharma customers.

TypeOthers
Description

Civica is a non-profit hospital-owned drug manufacturer whose mission is to address chronic drug shortages through contracted manufacturing partnerships. Although not a direct competitor, it is a strategic partner/distributor for Exela and a channel for its shortage-list injectables.

TypeEmerging player
Description

Kindeva is a CDMO specializing in injectable, inhalation, and transdermal drug delivery, with US sterile manufacturing capacity. It competes with Exela for sterile injectable CDMO contracts and recently supplied Exela's new Chief Quality Officer.

TypeEmerging player
Description

Aenova is a European-headquartered CDMO offering sterile liquid and lyophilized injectable manufacturing, as well as oral solids. It competes with Exela for pharma innovator CDMO business, particularly for companies seeking transatlantic manufacturing options.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exela Pharma Sciences

Sterile Injectable Pharmaceuticals Manufacturingexelapharma.com

Exela Pharma Sciences is a US-based specialty pharmaceutical company founded in 2005 that develops and manufactures proprietary and generic sterile injectable products and provides integrated CDMO services from over 400,000 square feet of cGMP capacity in Lenoir, North Carolina, serving hospitals, health systems, and pharmaceutical innovators via Premier, Civica Rx, and direct channels.

What Exela Pharma Sciences does

Exela Pharma Sciences, founded in 2005 and headquartered in Lenoir, North Carolina, is a US-based specialty pharmaceutical company that develops, manufactures, and markets proprietary and generic sterile injectable products and provides integrated contract development and manufacturing (CDMO) services to pharmaceutical innovators. The company operates two business units from a single 400,000+ square foot cGMP campus: a Finished Drug Products portfolio of more than 20 sterile injectables across ANDA, 505(b)(2) NDA, NDA, and 503B pathways (key brands include AKOVAZ, ELCYS, GLYRX-PF, NIPRIDE RTU, Bloxiverz, and Sodium Bicarbonate Injection) and a CDMO services division covering R&D, quality and regulatory, aseptic fill-finish (vials, IV bags, pre-filled syringes, lyophilization), and warehouse and logistics.

The technology base centers on cGMP sterile injectable manufacturing with isolator-based aseptic processing, high-speed automated vial and pre-filled syringe filling, DEA Schedule II-V controlled substance handling, terminal sterilization via high-capacity autoclaves, ultra-low-temperature biorepository storage, and integrated quality systems (LIMS, Empower chromatography, electronic quality system, ERP). The company has passed more than 15 FDA inspections since 2010 and is also approved by HealthCanada and the Australian TGA. Manufacturing capacity exceeds 100 million sterilized units per year, with disclosed excess capacity available for CDMO opportunities.

Exela generates revenue through two streams: sale of its own branded and generic injectable products to hospitals and health systems, and contract development and manufacturing services sold directly to pharmaceutical and biotech innovators. Products are distributed through Premier's group purchasing organization, Civica Rx (1,000+ hospital members), direct sales to health systems (including 11 health systems that are also minority investors in the parent holding company), and the company's own Exela Direct Store e-commerce platform. Pricing is negotiated through GPO contracts and direct quotes on multi-year terms; no public price list exists. The company has been subject to several voluntary recalls between 2022 and 2025 (particulate matter, vial breakage, and a Class I defective crimp recall), which represent an ongoing quality-execution consideration.

Exela Pharma Sciences firmographics

Firmographics
Name
Exela Pharma Sciences
Legal name
Exela Pharma Sciences, LLC
Website
https://exelapharma.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Exela Pharma Sciences is a US-based specialty pharmaceutical company founded in 2005 that develops and manufactures proprietary and generic sterile injectable products and provides integrated CDMO services from over 400,000 square feet of cGMP capacity in Lenoir, North Carolina, serving hospitals, health systems, and pharmaceutical innovators via Premier, Civica Rx, and direct channels.
Ownership category
akta.pro rank

Exela Pharma Sciences industry classification

Industry
Product category
Sterile Injectable Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile injectable manufacturing
  • Pharmaceutical contract manufacturing
  • Generic injectable products
  • Aseptic fill-finish services
  • CGMP pharmaceutical production

Where Exela Pharma Sciences is headquartered

Location

Headquarters

HQ city
Lenoir
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Exela Pharma Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Proprietary and Generic Sterile Injectable Products: Exela manufactures and markets its own branded sterile injectable pharmaceutical products (ANDA, 505(b)(2) NDA, NDA, 503B) including sodium bicarbonate, caffeine citrate, ephedrine sulfate, glycopyrrolate, neostigmine, cysteine, and other injectables sold to healthcare providers and health systems.
  2. CDMO Contract Development and Manufacturing Services: Exela provides contract development and manufacturing services to pharmaceutical companies, offering integrated drug formulation, analytical, aseptic fill-finish, lyophilization, and regulatory services from early-phase through commercialization.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractExela-branded pharmaceutical products sold via GPO and direct accounts

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Exela Pharma Sciences product offering

Product offering

Core offering

Exela Pharma Sciences develops, manufactures, and markets proprietary and generic sterile injectable pharmaceutical products in liquid vials, IV bags, lyophilized vials, and pre-filled syringes. The company also operates a CDMO business providing contract development, cGMP aseptic manufacturing, quality/regulatory, and warehouse/logistics services to pharmaceutical innovators from its Lenoir, North Carolina facilities.

Product overview

Exela Pharma Sciences operates two distinct business units: Finished Drug Products (proprietary and generic sterile injectables) and Contract Development and Manufacturing Organization (CDMO). The Finished Drug Products portfolio includes 20+ sterile injectable products marketed via ANDA, 505(b)(2) NDA, and 503b pathways. Key branded products include AKOVAZ (ephedrine sulfate), ELCYS (cysteine hydrochloride - only FDA approved cysteine injection), GLYRX-PF (glycopyrrolate), and NIPRIDE RTU (sodium nitroprusside). The CDMO services division provides end-to-end contract services including R&D (analytical, microbiology, formulation), cGMP manufacturing (vials, IV bags, prefilled syringes, lyophilization), quality/regulatory support, and warehouse/logistics from their Lenoir, NC facilities. The company manufactures liquid vials, lyophilized vials, IV bags, and pre-filled syringes.

Differentiator

Problem solved

Functional benefit

Products and services

  • ELCYS (cysteine hydrochloride) Injection, USP 500 mg/10mL (50 mg/mL) single-dose vial of cysteine hydrochloride injection used as an additive to amino acid solutions for TPN; the only FDA-approved cysteine hydrochloride injection in the US market with aluminum content of no more than 120 parts per billion, addressing aluminum toxicity risk in parenteral nutrition patients.
  • AKOVAZ (ephedrine sulfate) Injection Ephedrine sulfate injection available in 25 mg/5mL pre-filled syringe and 50 mg/mL single-dose vial presentations; a clear, colorless, sterile solution used for pressor support during anesthesia.
  • Bloxiverz (Neostigmine Methylsulfate) Prefilled Syringe Pre-filled syringe of neostigmine methylsulfate injection USP for reversal of neuromuscular blockade following surgical procedures.
  • GLYRX-PF (glycopyrrolate injection) Glycopyrrolate injection available in 1 mg/5mL pre-filled syringe, 0.2 mg/mL single-dose vial, and 0.4 mg/2mL single-dose vial presentations; used for anticholinergic indications including reduction of airway and gastric secretions during anesthesia.
  • NIPRIDE RTU (sodium nitroprusside) Injection Ready-to-use sodium nitroprusside injection in 50 mg/100mL (0.5 mg/mL) and 20 mg/100mL (0.2 mg/mL) amber single-dose vials; sterile, unpreserved, colorless to red-brown solution for immediate blood pressure control.
  • Sodium Bicarbonate Injection, USP Sodium bicarbonate injection in 4.2% (5 mEq/10mL) and 8.4% (50 mEq/50mL and 10 mEq/10mL) single-dose vial presentations; clear, sterile, nonpyrogenic, hypertonic solution for treatment of metabolic acidosis.
  • Caffeine Citrate Injection and Oral Solution, USP Caffeine citrate 60 mg/3mL (20 mg/mL) injection vial and oral solution for treatment of neonatal apnea in premature infants.
  • Tranexamic Acid Injection, IV Bag Tranexamic acid 1000 mg/100mL (10 mg/mL) single-dose polymeric IV bag for antifibrinolytic therapy to reduce or prevent hemorrhage.
  • Potassium Acetate Injection, USP Potassium acetate injection USP in 40 mEq/20mL (2 mEq/mL) single-dose vials and 200 mEq/100mL (2 mEq/mL) pharmacy bulk vials for electrolyte replacement in IV admixtures.
  • Verapamil Hydrochloride Injection, USP Verapamil hydrochloride injection USP 5 mg/2mL (2.5 mg/mL) single-dose vial for antiarrhythmic and cardiovascular use.
  • Cupric Chloride Injection, USP Cupric chloride injection USP 4mg/10mL (0.4 mg/mL) single-dose plastic vial of sterile, nonpyrogenic solution for trace element supplementation in parenteral nutrition.
  • Zinc Chloride Injection, USP Zinc chloride injection USP 10 mg/10mL (1 mg/mL) single-dose vial for trace element supplementation in parenteral nutrition.
  • CDMO Research and Development Services Full-service R&D offering including small and large molecule capabilities, analytical services, microbiology labs, drug formulation development, and pre-formulation studies for parenteral, liquid, and lyophilized formulations; serves pharmaceutical and biotech innovators.
  • CDMO cGMP Manufacturing Services cGMP parenteral drug product contract manufacturing including medium- and high-speed vial filling, IV bag filling, pre-filled syringe filling, lyophilization, aseptic and terminal sterilization, Schedule II-IV DEA controlled substance handling, stability programs, and automated inspection/labeling/packaging.
  • CDMO Quality and Regulatory Services Quality and regulatory support with 15+ FDA inspections since 2010, experience with 505(b)(2) NDAs and ANDAs, regulatory filings for sterile injections, electronic quality systems, and pharmacovigilance for life science innovators.
  • CDMO Warehouse and Logistics Services Warehousing, biorepository storage at ultra-low temperatures (-80°C to -70°C) and 2-8°C, temperature-controlled storage, global distribution, and cold chain capabilities for pharmaceutical and biotech customers.

Quantifiable outcome

  • Over 100 million sterilized units per year manufacturing capacity with significant excess capacity for CDMO
  • +3 more outcomes

Companies that use Exela Pharma Sciences

Customer profile

Named customers13 records

Segments3 records

Ideal customer profiles3 records

Exela Pharma Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Exela Pharma Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Civica RxcoreChannel Partner/ Reseller/ Distributor · 11 September 2019Civica Rx, a non-profit organization formed in 2018 with mission to solve chronic drug shortages, signed a long-term agreement with Exela for distribution of Sodium Bicarbonate Injection to Civica's 1,000+ hospital members under the Civica label. Distribution began Q4 2019.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Exela Pharma Sciences competitors and assessment

Company assessment

Direct peers

  • Amphastar Pharmaceuticals: Amphastar is a US-based specialty pharmaceutical company focused on injectable, inhalation, and intranasal products, including generic sterile injectables sold to hospitals. It directly overlaps with Exela's proprietary/generic sterile injectable portfolio and its hospital-channel GTM motion.
  • Fresenius Kabi: Fresenius Kabi is a global leader in sterile injectable generics, IV solutions, and parenteral nutrition, selling to hospitals and health systems worldwide. It competes head-to-head with Exela in generic sterile injectables (e.g., sodium bicarbonate) and large-volume parenterals sold through GPOs.
  • Hikma Pharmaceuticals: Hikma is a multinational generic pharmaceutical manufacturer with a large US injectable portfolio sold to hospitals. It directly competes with Exela's branded and generic sterile injectable products through similar GPO and hospital channels.
  • B. Braun Medical: B. Braun is a major manufacturer of sterile injectables, IV solutions, and parenteral nutrition products with significant US manufacturing capacity. It competes directly with Exela in the hospital sterile injectable space and also operates its own CDMO capabilities.
  • Catalent: Catalent is a major global CDMO offering sterile fill-finish, prefilled syringe, and lyophilization services to pharma and biotech innovators. It competes with Exela's CDMO services for sterile injectable development and manufacturing contracts.
  • Patheon (Thermo Fisher Scientific): Patheon, now part of Thermo Fisher's pharma services segment, is a leading global CDMO offering sterile injectable development, aseptic fill-finish, and commercial manufacturing. It directly competes with Exela's CDMO services for biotech and pharma customers.

Broad incumbents

  • Pfizer Injectables (formerly Hospira): Pfizer's Injectables portfolio, inherited from Hospira, is the largest US hospital injectable franchise, offering a broad sterile injectable portfolio plus global CDMO services. It overlaps with Exela's portfolio and CDMO business as a much larger incumbent player.

Others

  • Civica Rx: Civica is a non-profit hospital-owned drug manufacturer whose mission is to address chronic drug shortages through contracted manufacturing partnerships. Although not a direct competitor, it is a strategic partner/distributor for Exela and a channel for its shortage-list injectables.

Emerging players

  • Kindeva Drug Delivery: Kindeva is a CDMO specializing in injectable, inhalation, and transdermal drug delivery, with US sterile manufacturing capacity. It competes with Exela for sterile injectable CDMO contracts and recently supplied Exela's new Chief Quality Officer.
  • Aenova Group: Aenova is a European-headquartered CDMO offering sterile liquid and lyophilized injectable manufacturing, as well as oral solids. It competes with Exela for pharma innovator CDMO business, particularly for companies seeking transatlantic manufacturing options.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Exela Pharma Sciences social profiles

Digital presence

Exela Pharma Sciences compliance and trust

Trust signal

Compliance3 records

Exela Pharma Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exela Pharma Sciences leadership team

Management profile

Number of profiles

Profiles9 records

Exela Pharma Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exela Pharma Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exela Pharma Sciences

What does Exela Pharma Sciences do?

Exela Pharma Sciences develops, manufactures, and markets proprietary and generic sterile injectable pharmaceutical products in liquid vials, IV bags, lyophilized vials, and pre-filled syringes. The company also operates a CDMO business providing contract development, cGMP aseptic manufacturing, quality/regulatory, and warehouse/logistics services to pharmaceutical innovators from its Lenoir, North Carolina facilities.

Is Exela Pharma Sciences a public or private company?

Exela Pharma Sciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Exela Pharma Sciences founded?

Exela Pharma Sciences was founded in 2005. It employs 501 to 1,000 people.

Where is Exela Pharma Sciences based?

Exela Pharma Sciences is headquartered in Lenoir, United States, in the North America region.

How does Exela Pharma Sciences make money?

Two revenue lines are on record. Proprietary and Generic Sterile Injectable Products are the primary driver. The others are CDMO Contract Development and Manufacturing Services.

Who are Exela Pharma Sciences's main competitors?

Direct peers on record are Amphastar Pharmaceuticals, Fresenius Kabi, Hikma Pharmaceuticals, B. Braun Medical, Catalent and Patheon (Thermo Fisher Scientific). Pfizer Injectables (formerly Hospira) is listed as a broad incumbent. Civica Rx is listed as an others. Emerging players are Kindeva Drug Delivery and Aenova Group.

Does Exela Pharma Sciences have an API?

No public API is recorded for Exela Pharma Sciences.

What industry is Exela Pharma Sciences in?

Exela Pharma Sciences's product category is Sterile Injectable Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Sustainable Packaging NewsIL Group Delivers Tamper-Evident Labeling Solution for Exela Pharma Sciences’ Prefilled Syringe LaunchIL Group, a specialist in pharmaceutical labeling solutions, partnered with Exela Pharma Sciences to develop custom tamper-evident shrink film labels for the company's new prefilled syringe products. The solution addressed a critical gap—Exela's COC syringes lacked pre-installed tamper-evident features required for regulatory approval—by creating labels compatible with existing production equipment, avoiding costly modifications. The partnership enabled Exela to successfully launch its prefilled syringe products on schedule while meeting growing demand for safe, secure drug delivery systems.TracxnTop Companies in Generic Injectables (Jul, 2025)The article presents a ranked list of top generic injectables startups, highlighting ImprimisRx, Sagent Pharma, Exela Pharma, and Zenotech Laboratories along with their key operational and financial metrics. It notes that these entities have received varying levels of funding, with Sagent Pharma having raised the most at $153M, while others like ImprimisRx and Exela Pharma have secured smaller amounts or are in earlier stages. The report also mentions that several of these companies were founded by alumni from institutions such as BITS Pilani, Columbia Business School, and IIM Bangalore.GenengnewsRecipharm and Exela Pharma Sciences Form Exclusive CDMO Strategic AllianceRecipharm and Exela Pharma Sciences have formed an exclusive strategic alliance to combine their CDMO sterile manufacturing capabilities in the United States, giving Recipharm access to Exela's FDA-accredited facility in Lenoir, North Carolina. The facility, which manufactures sterile injectable pharmaceuticals in vial and pre-filled syringe formats, offers over 100 million units of production capacity and is expanding into biopharmaceuticals including antibody drug conjugates, GLP-1 drugs, vaccines, and biologics. Recipharm will contribute its analytical capabilities, commercial expertise, and MSAT support, while its biologics division ReciBioPharm will add advanced therapy medicinal product capabilities to serve both U.S. and international pharmaceutical customers.PremierincPremier Inc. and 11 Leading Health Systems Invest in Exela Pharma Sciences to Secure and Support U.S.-Based Drug Supply and ManufacturingPremier Inc. and 11 leading health systems acquired a minority stake in Exela Holdings, Inc., the holding company of Exela Pharma Sciences, to secure the supply of pharmaceutical products and support domestic manufacturing. This investment aims to provide participating members with uninterrupted access to critical generic injectables and address persistent drug shortages by leveraging Exela's U.S.-based production capacity. The partnership involves multi-year purchase commitments from the health systems through Premier’s group purchasing organization.Business Wire BlogPremier Inc. and 11 Leading Health Systems Invest in Exela Pharma Sciences to Secure and Support U.S.- Based Drug Supply and ManufacturingPremier Inc. and 11 leading health systems have acquired a minority stake in Exela Holdings, Inc. to secure the supply of pharmaceutical products and support domestic manufacturing. This investment ensures uninterrupted access to 19 critical pharmaceutical products for participating members while bolstering U.S.-based production infrastructure. The initiative aims to mitigate pervasive drug shortages that have previously resulted in sub-optimal patient outcomes and significant additional annual costs.PR NewswireGlobal Spinal Fusion Pipeline Insight 2020: Current Treatment Patterns, Pre-Clinical and Discover Stage Products and Key Products and CompaniesResearchAndMarkets.com has added the "Spinal Fusion - Pipeline Insight, 2020" report to its offerings. The report provides a comprehensive analysis of the spinal fusion market, including clinical development scenarios, growth prospects, and detailed profiles of therapeutic products from pre-clinical to marketed phases. It highlights key players such as Exela Pharma Sciences, Spinemark Corporation, Bone Therapeutics, Novadip Biosciences, and Prosidyan in the context of their R&D activities.GlobeNewswireAvadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 MillionAvadel Pharmaceuticals sold its hospital sterile injectable drug portfolio to Exela Sterile Medicines for $42.0 million, including three commercial products and Nouress. The deal closed June 30, 2020, with $14.5 million upfront and $27.5 million over 13 months. Avadel will focus on advancing FT218, its once-nightly sodium oxybate formulation for narcolepsy.GlobeNewswireEton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection)Eton Pharmaceuticals confirmed as first filer of an ANDA challenging Exela Pharma Sciences' Elcys patent, citing Paragraph IV certifications. Eton plans Post Grant Reviews, potentially allowing a 2021 launch if patents are invalidated. The market is estimated over $50 million annually.